Synthego CEO Paul Dabrowski. Photo credit: Stuart Isett for Fortune, under Creative Commons license

Synthego, a Redwood City, California-based genome engineering upstart, has raised $100 million in Series D funding from investors including Wellington Management, 8VC, Founders Fund, Menlo Ventures, and Intel Capital. The new funding brings the total amount that Synthego has raised since its inception to more than $250 million. The company says it’ll use the new capital to expand its genome engineering operations.

Synthego is a developer of precision tools used to automate genome engineering research. The company was founded in 2012 by brothers Paul and Michael Dabrowski, who were previously engineers at aerospace company SpaceX. Synthego has its eyes set on accelerating research and development of less costly gene therapies through a combo of automation, machine learning, and engineered biology. Over the past few years, Synthego has partnered with many medical institutions and also Fortune 500 biopharmaceutical companies to further its cause.

As of recent, Synthego has notably added two industry veterans to its coffers, by the names of Robert Deans, who now serves as Chief Scientific Officer; and John Tan, who serves as Chief Operating Officer. Synthego is ultimately led by CEO Paul Dabrowski, notably a computer engineer by training. His brother, Michael, serves as Synthego’s President.